Apimeds Pharmaceuticals Files S-1/A Amendment

TL;DR

Apimeds Pharma filed an S-1/A amendment on Feb 10, 2025. IPO/secondary offering incoming?

AI Summary

Apimeds Pharmaceuticals US, Inc. filed an S-1/A amendment on February 10, 2025, for its registration statement (No. 333-282324). The company, incorporated in Delaware with its principal executive offices in Hopewell, NJ, is in the pharmaceutical preparations industry. This filing is an amendment to a previous registration, indicating ongoing efforts to go public or issue new securities.

Why It Matters

This S-1/A filing is a step in the process for Apimeds Pharmaceuticals to potentially offer its securities to the public, which could impact investors and the pharmaceutical market.

Risk Assessment

Risk Level: medium — S-1/A filings are typically associated with initial public offerings or significant capital raises, which inherently carry market and execution risks.

Key Numbers

• 333-282324 — SEC File Number (Identifies the specific registration statement being amended.)
• 08425 — ZIP Code (Part of the principal executive office address in Hopewell, NJ.)

Key Players & Entities

• Apimeds Pharmaceuticals US, Inc. (company) — Registrant
• February 10, 2025 (date) — Filing Date
• 333-282324 (registration_number) — SEC File Number
• 2 East Broad Street 2nd Floor Hopewell, NJ 08425 (address) — Principal Executive Offices
• Erik Emerson (person) — Chief Executive Officer

FAQ

Key Financial Figures

• $4.00 — ing price of our shares will be between $4.00 and $5.00. We intend to apply to have
• $5.00 — of our shares will be between $4.00 and $5.00. We intend to apply to have our commo
• $6.0 million — ase up to an aggregate of approximately $6.0 million of shares of our common stock in this o
• $8.28 — the United States accounted for $8.28 billion in 2022 and it is expect
• $20.24 — n 2022 and it is expected to hit around $20.24 billion by 2032, expanding at a
• $10.73 — the United States accounted for $10.73 billion in 2022 and is expected
• $24.4 — ;billion in 2022 and is expected to hit $24.4 billion by 2030, expanding at a

Filing Documents

• ea0201124-15.htm (S-1/A) — 4023KB
• ea020112415ex1-1_apimeds.htm (EX-1.1) — 457KB
• tapimeds_logo.jpg (GRAPHIC) — 91KB
• tboral_logo.jpg (GRAPHIC) — 77KB
• ttable_01.jpg (GRAPHIC) — 994KB
• tflowchart_001.jpg (GRAPHIC) — 266KB
• 0001213900-25-011555.txt ( ) — 6447KB

RISK FACTORS

RISK FACTORS   11 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS   48

USE OF PROCEEDS

USE OF PROCEEDS   51 REVERSE STOCK SPLIT   52 DIVIDEND POLICY   52 CAPITALIZATION   53

DILUTION

DILUTION   54 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   56

BUSINESS

BUSINESS   66 MANAGEMENT   91

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION   98 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS   104 PRINCIPAL STOCKHOLDERS   108

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK   110 SHARES ELIGIBLE FOR FUTURE SALE   112 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS   114

UNDERWRITING

UNDERWRITING   117 LEGAL MATTERS   125 EXPERTS   125 WHERE YOU CAN FIND MORE INFORMATION   125 INDEX TO FINANCIAL STATEMENTS   F-1 You should rely only on the information contained in this prospectus. We and the underwriters have not authorized any other person to provide you with information different from or in addition to that contained in this prospectus, and we take no responsibility for any other information others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. We and the underwriters are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. No action is being taken in any jurisdiction outside the United States to permit a public offering of our common stock or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. i Table of Contents PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, including the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and the related notes included elsewhere in this prospectus, before ma

View Full Filing

View this S-1/A filing on SEC EDGAR